File downloaded on 2025-12-24

Source URL: https://medicines.health.europa.eu/veterinary/en/600000061257

Spasmalgan compositum 500 mg/ml + 4 mg/ml Solution for injection for horses, cattle, pigs and dogs



- Hyoscine butylbromide
- Metamizole sodium monohydrate

Product identification

Medicine name:

Spasmalgan compositum 500 mg/ml \pm 4 mg/ml Solution for injection for horses, cattle, pigs and dogs

Spasmalgan compositum 500 mg/ml + 4 mg/ml Injekčný roztok pre kone, hovädzí dobytok, ošípané a psy

Active substance:

Hyoscine butylbromide

Metamizole sodium monohydrate

Target species:

Cattle

Dog

Horse

Pig

Route of administration:

Product details

Active substance and strength:

Hyoscine butylbromide 4.00 milligram(s) / 1.00 millilitre(s)

Metamizole sodium monohydrate 500.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration: . .

Intravenous use:

Cattle

- Milk. 96 hour
- Meat and offal. 12 day

•

Horse

- Meat and offal. 12 day
- Milk. no withdrawal period

Not authorised for use in horses producing milk for human consumption.

Intramuscular use:

Pig

- Meat and offal. 15 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QA03DB04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Slovakia

Available in:

Slovakia

Package description:

(ID2) 100 millilitre(s): Box (board) with 1 Bottle (clear glass) with 100 millilitre(s), closed with Stopfen (bromobutyl rubber) and Cap`` (aluminium) (ID1) 10 millilitre(s): Box (board) with 1 Bottle (clear glass) with 10 millilitre(s), closed with Stopfen (bromobutyl rubber) and Cap`` (aluminium)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Veyx Pharma GmbH

Marketing authorisation date:

7/08/2020

Manufacturing sites for batch release:

Veyx Pharma GmbH Veyx-Pharma B.V.

Responsible authority:

Institute For State Control Of Veterinary Biologicals And Medicaments

Authorisation number:

96/024/DC/20-S

Date of authorisation status change:

10/10/2022

Reference member state:

Germany

Procedure number:

DE/V/0323/001

Concerned member states:

Austria Bulgaria Croatia Cyprus Czechia Estonia Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta Poland Portugal Romania Slovakia Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 4/12/2025

Download